Patient-level micro-simulation model for evaluating the future potential cost–effectiveness of pharmacy-based interventions in the control and management of diabetes-related complications in Canada

Abstract

AbstractBackgroundThe increased risk of complications among diabetes patients poses a serious threat to population health. Pharmacy-based interventions can decrease the burden of diabetes and its related complications. This study evaluates the cost-effectiveness of pharmacy-based interventions and offers insights on the practicality of their adoption by health practitioners.MethodsWe developed population-based micro-simulation model using 2,931 patients with diabetes in Canada. We used the risk equations on the UK Prospective Diabetes Study (UKPDS) to estimate the incidence and mortality of four of the most common diabetes-related complications (heart failure, stroke, amputation, and blindness). We extrapolated the potential effects of pharmacy interventions on reducing time-varying risk factors for diabetes complications. Cost was quantified as the annual cost of complications; and, the cost associated with pharmacy-based interventions. The final outcomes were the incremental costs per quality-adjusted life years (QALY) gained. Both deterministic and probabilistic sensitivity analysis were conducted to examine the robustness of the ratio.ResultPharmacy-based interventions could prevent 155 preventable deaths, 159 strokes, 29 cases of blindness, 24 amputations, and 19 heart failures across the lifetime of 2,931 patients. In addition, an estimated 953 QALYs (0.32 per patient) would be gained among the intervention group. Per QALY, the incremental discounted cost is $3,928, suggesting that pharmacy-based interventions are likely cost-effective compared to usual care. At an ICER threshold of $50,000, over 92% of the simulation remains cost-effective.ConclusionPharmacist-based interventions targeted at addressing the development of diabetes-related complications among Canadian patients have the potential to offer a cost-effective strategy.